Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
性状
Liquid
体外研究(In Vitro)
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability AssayCell Line:
体内研究(In Vivo)
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13.[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354.